ECSP11011403A - Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia - Google Patents

Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia

Info

Publication number
ECSP11011403A
ECSP11011403A EC2011011403A ECSP11011403A ECSP11011403A EC SP11011403 A ECSP11011403 A EC SP11011403A EC 2011011403 A EC2011011403 A EC 2011011403A EC SP11011403 A ECSP11011403 A EC SP11011403A EC SP11011403 A ECSP11011403 A EC SP11011403A
Authority
EC
Ecuador
Prior art keywords
leukemia
benzodiazepine
treatment
mixed lineage
hematopoyetic
Prior art date
Application number
EC2011011403A
Other languages
English (en)
Inventor
Marcio Chedid
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174602&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011403A publication Critical patent/ECSP11011403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un método y medicamento para el tratamiento de leucemia de linaje mezclado; leucemia de linaje mezclado translocado; leucemia mielógena aguda basada en leucemia de linaje mezclado translocado; leucemia linfoide aguda basada en leucemia de linaje mezclado translocado; trastorno mieloproliferativo crónico no basado en MLL, o leucemia linfoide aguda no basada en MLL se provee, en donde el agente activo usado es el inhibidor de GSK-3 7-(2,5-dihidro-4-imidazo[1,2-a]piridina-3-il-2,5-dioxo-lH-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinilcarbonil)-pirrolo[3,2,1-jk][1,4]benzodiazepina o una sal farmacéuticamente aceptable o un solvato del mismo.
EC2011011403A 2009-04-14 2011-08-14 Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia ECSP11011403A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16909409P 2009-04-14 2009-04-14

Publications (1)

Publication Number Publication Date
ECSP11011403A true ECSP11011403A (es) 2011-11-30

Family

ID=42174602

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011403A ECSP11011403A (es) 2009-04-14 2011-08-14 Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia

Country Status (23)

Country Link
US (2) US8802668B2 (es)
EP (1) EP2419106A1 (es)
JP (1) JP5699129B2 (es)
KR (1) KR101290509B1 (es)
CN (1) CN102395372B (es)
AU (1) AU2010236747B2 (es)
BR (1) BRPI1013774A2 (es)
CA (1) CA2758473C (es)
CL (1) CL2011002531A1 (es)
DO (1) DOP2011000312A (es)
EA (1) EA018933B1 (es)
EC (1) ECSP11011403A (es)
IL (1) IL215107A0 (es)
MA (1) MA33184B1 (es)
MX (1) MX2011010937A (es)
MY (1) MY157218A (es)
NZ (1) NZ595413A (es)
PE (1) PE20120772A1 (es)
SG (1) SG175207A1 (es)
TN (1) TN2011000500A1 (es)
TW (1) TWI453022B (es)
UA (1) UA103792C2 (es)
WO (1) WO2010120614A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290509B1 (ko) * 2009-04-14 2013-07-26 일라이 릴리 앤드 캄파니 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체
US9446048B2 (en) 2011-03-17 2016-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
CN102887896B (zh) * 2012-10-26 2015-11-18 南京工业大学 一种2-（咪唑并[1,2-a]吡啶-3-基）乙腈的制备方法
CA2892927A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
CN104945436B (zh) * 2015-07-09 2017-02-08 山东罗欣药业集团股份有限公司 一种米诺膦酸的制备方法
KR101694063B1 (ko) 2015-10-12 2017-01-17 전남대학교병원 Ｂｉｏ 화합물을 함유하는 심혈관질환의 치료용 조성물
EP3534887B1 (en) 2016-11-03 2023-09-20 UCL Business Ltd Cancer therapy for mixed lineage leukemia
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ATE346070T1 (de) * 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
CA2707554C (en) 2007-12-05 2015-06-30 Gerd Dannhardt Use of 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
KR101290509B1 (ko) * 2009-04-14 2013-07-26 일라이 릴리 앤드 캄파니 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체

Also Published As

Publication number Publication date
CL2011002531A1 (es) 2012-06-01
US9044487B2 (en) 2015-06-02
MY157218A (en) 2016-05-13
CN102395372B (zh) 2014-07-02
UA103792C2 (uk) 2013-11-25
CN102395372A (zh) 2012-03-28
US20140235621A1 (en) 2014-08-21
PE20120772A1 (es) 2012-06-27
DOP2011000312A (es) 2011-10-31
EP2419106A1 (en) 2012-02-22
AU2010236747B2 (en) 2012-11-08
SG175207A1 (en) 2011-11-28
KR101290509B1 (ko) 2013-07-26
MA33184B1 (fr) 2012-04-02
JP5699129B2 (ja) 2015-04-08
WO2010120614A1 (en) 2010-10-21
KR20120004447A (ko) 2012-01-12
MX2011010937A (es) 2011-11-02
TN2011000500A1 (en) 2013-05-24
EA018933B1 (ru) 2013-11-29
CA2758473C (en) 2013-12-17
IL215107A0 (en) 2011-12-29
NZ595413A (en) 2013-05-31
AU2010236747A1 (en) 2011-10-06
CA2758473A1 (en) 2010-10-21
US8802668B2 (en) 2014-08-12
BRPI1013774A2 (pt) 2016-04-05
JP2012524089A (ja) 2012-10-11
TW201105328A (en) 2011-02-16
US20100261712A1 (en) 2010-10-14
EA201171243A1 (ru) 2012-03-30
TWI453022B (zh) 2014-09-21

Similar Documents

Publication Publication Date Title
ECSP11011403A (es) Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2015012636A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazol[1,2-a] pirido [4,3-d] pirimidin-5(3h)-ona.
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2021001952A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
AR084551A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DUAL DE mTOR/CINASA PI3
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
CY1124832T1 (el) 7-βενζυλο-4-(2-μεθυλοβενζυλο)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1 η)-ονη, τα αλατα της και οι μεθοδοι χρησης τους σε συνδυαστικη θεραπεια
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CL2008003575A1 (es) Compuestos derivados de 1,5-dihidropirazolo[3,4-d]piridin-4-ona, inhibidores de pde9a; composicion farmaceutica que los comprende; y su uso en el tratamiento y prevencion del alzheimer, parkinson, esclerosis multiple, demencia vascular, esquizofrenia con demencia, entre otras.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
MX2015012899A (es) Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9.
MX2020006228A (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12018502111A1 (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2010033219A3 (en) Protease inhibitors having enhanced features
CL2018002441A1 (es) Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5
PH12018501490A1 (en) Use of inhibitors of the activity or function of pi3k for the treatment of primary sj™gren's syndrome
Wermes Panaritium: case report